OPKO HEALTH, INC.(OPK)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,730 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
OPK Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for OPKO HEALTH, INC. (OPK), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores OPK at 23.3/100 on a 32-signal composite quality model, placing it at rank #2,730 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include earnings quality (2.8) and revenue growth (8.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 42.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), OPKO HEALTH, INC. reports quarterly revenue of $163.6M, net income of $-8.4M, free cash flow of $-46.5M. Top institutional holders of OPK by reported 13-F value include Rubric Capital Management, BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. OPK trades on the Nasdaq exchange and files with the SEC under CIK 944809. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OPK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for OPKO HEALTH, INC. directly from SEC EDGAR. OPKO HEALTH, INC.'s 13F Pro composite quality score has ranged between 19 and 61 since 2021, currently 23.3 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$163.6M
Net Income
Q2 2026
$-8.4M
Free Cash Flow
Q2 2026
$-46.5M
ROIC
Q2 2026
-1.8%
D/E Ratio
Q2 2026
0.30
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-14.9% YoYNet Income
-324.0% YoYOperating Income
+22.8% YoYEPS (Diluted)
-275.0% YoYTotal Assets
-12.2% YoYTotal Debt
-60.5% YoYOp. Cash Flow
+2.7% YoYFree Cash Flow
+8.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $606.9M -14.9% | $713.1M -17.4% | $863.5M -14.0% | $1.00B -43.4% | $1.77B +23.6% | $1.44B |
| Net Income | $-225.7M -324.0% | $-53.2M +71.8% | $-188.9M +42.5% | $-328.4M -989.5% | $-30.1M -198.6% | $30.6M |
| Operating Income | $-117.4M +22.8% | $-152.1M +3.2% | $-157.0M +30.6% | $-226.3M -1306.7% | $18.8M -67.5% | $57.7M |
| EPS (Diluted) | $-0.30 -275.0% | $-0.08 +68.0% | $-0.25 +45.7% | $-0.46 -820.0% | $-0.05 -200.0% | $0.05 |
| Total Assets | $1.93B -12.2% | $2.20B +9.4% | $2.01B -7.2% | $2.17B -9.7% | $2.40B -3.0% | $2.47B |
| Total Debt | $345.7M -60.5% | $874.4M +8895.9% | $9.7M -96.2% | $258.0M +25.7% | $205.3M -18.3% | $251.2M |
| Operating Cash Flow | $-178.5M +2.7% | $-183.5M -550.7% | $-28.2M +70.4% | $-95.2M -348.3% | $38.3M -2.9% | $39.5M |
| Free Cash Flow | $-190.8M +8.5% | $-208.5M -368.8% | $-44.5M +62.9% | $-119.8M -2037.7% | $6.2M +6.7% | $5.8M |
Get alerted when OPK's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for OPKO HEALTH, INC. including:
Top Institutional Holders of OPK
Rubric Capital Management LP
$71.7M47,791,243 shBlackRock, Inc.
$55.5M36,978,893 shVANGUARD CAPITAL MANAGEMENT LLC
$22.5M14,968,930 shVANGUARD PORTFOLIO MANAGEMENT LLC
$22.4M14,934,924 shWOLVERINE ASSET MANAGEMENT LLC
$20.4M13,785,000 shGEODE CAPITAL MANAGEMENT, LLC
$17.4M11,581,027 shSTATE STREET CORP
$15.5M10,309,070 shWhitefort Capital Management, LP
$14.1M9,350,000 shPenderFund Capital Management Ltd.
$12.8M8,491,000 shGOLDMAN SACHS GROUP INC
$10.6M7,035,492 sh
| Fund | Value | Shares |
|---|---|---|
| Rubric Capital Management LP | $71.7M | 47,791,243 |
| BlackRock, Inc. | $55.5M | 36,978,893 |
| VANGUARD CAPITAL MANAGEMENT LLC | $22.5M | 14,968,930 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $22.4M | 14,934,924 |
| WOLVERINE ASSET MANAGEMENT LLC | $20.4M | 13,785,000 |
| GEODE CAPITAL MANAGEMENT, LLC | $17.4M | 11,581,027 |
| STATE STREET CORP | $15.5M | 10,309,070 |
| Whitefort Capital Management, LP | $14.1M | 9,350,000 |
| PenderFund Capital Management Ltd. | $12.8M | 8,491,000 |
| GOLDMAN SACHS GROUP INC | $10.6M | 7,035,492 |
Companies Similar to OPK
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
NOVAVAX INC
Orthofix Medical Inc.
SIGA TECHNOLOGIES INC
Xtant Medical Holdings, Inc.
QuidelOrtho Corp
Canopy Growth Corp
Sarepta Therapeutics, Inc.
Inotiv, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put OPK on your watchlist
Track score changes the day OPKO HEALTH, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is OPK a good stock to buy?
13F Pro's AI-powered analysis of OPKO HEALTH, INC. (OPK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OPK are available on the OPK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. OPK is classified as a small company.
Which hedge funds own OPK?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OPK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of OPKO HEALTH, INC.'s investment landscape.